“…Monitoring and screening for CAH patients by measuring levels of 17α‐hydroxyprogesterone (17OHP) or other steroids has become a routine part of many programmes 1,. 2 Numerous methods have been described to determine these steroid hormones, such as fluorimetry,3,, 4 radioimmunoassay (RIA),5–8 and high‐performance liquid chromatography (HPLC) 4,. 9,, 10 Most of these, however, are affected by a degree of interference or cross‐reactivity with other steroids.…”